HUMAN LEUKOCYTE ANTIGEN-B27 AND DISEASE SUSCEPTIBILITY IN VOJVODINA, SERBIA
Vojvodić S1,*, Ademović-Sazdanić D1, Busarčević I2
*Corresponding Author: Assistant Professor Svetlana Vojvodić, M.D., Ph.D., Department for Laboratory Testing, Tissue Typing Compartment, Institute for Blood Transfusion of Vojvodina, Hajduk Veljkova 9a, 21000 Novi Sad, Serbia; Tel.: +381-21-4877-963; Mobile: +381-64-861-58-12; Fax: +381-21-4877-978; E-mail: ssvu@EUnet.rs
page: 55

MATERIALS AND METHODS

Ninety-seven patients, of whom 58 were male and 39 were female, with a mean age of 39.6 14.4 years, suffering from different diseases: AS (16), polyarthralgia (34), lumboishialgia (14), AAU (11), PA (3), synovitis coxae (16) and RA (3), composed of different ethnicities, residents of different parts of Vojvodina, were included in our study. In addition, a group of 224 healthy, unrelated potential bone marrow/organ donors, representing the same ethnic groups as the patients who resided in the same geographic area, served as a control population. An informed consent was obtained from all the individuals participating in the study and all institutional ethics requirements were met. Three mililiters of venous blood taken in vacutainers with EDTA as anticoagulant was collected from the patients and controls. Peripheral mononuclear cells were isolated by ficoll hypaque gradient centrifugation from which the T lymphocytes were separated by immunomagnetic beads (Dynabeads, HLA class I typing was performed by serological immunomagnetic two-color fluorescence method using peripheral blood T lymphocytes and antigenspecific commercially available sera defining a single HLA specificity. Briefly, Terasaki microtiter plates (Inno- Train Diagnostik GmbH, Kronberg, Germany), containing various anti-HLA class I antisera were seeded with 1 mL of a 2 × 106 cells/mL suspension of immobilized T-cells. After incubation at room temperature and addition of 5 mL rabbit complement, the lysed and vital lymphocytes were assessed using an ethidium bromide/acridine orange dye (Merck, Darmstadt, Germany) under an inverse phase contrast microscope [10,11]. Phenotype frequencies were obtained by a direct counting method, according to equation: A = n/N, where n is number of persons with a given antigen and N is total number of persons studied. The strength of association of disease with respect to a particular HLAs is expressed by odds ratio (OR) interpreted as relative risk (RR). Relative risk is calculated for those HLAs that are increased or decreased in patients as compared to the control group. The RR or the number of times risk of disease is increased or decreased in individuals with a certain HLA marker, was calculated according to following formula where P+ and C+ are the number of patients or healthy persons who have a given antigen; C and P are the number of patients or healthy persons who do not have a given antigen, respectively [12,13,14]. The values between 0 and 1 are of significance. When RR was higher than 1, we calculated an etiological fraction (EF) or population attributive risk, according to formula: where FAD is the frequency of the HLA-B27 antigen in the subgroup of patients and FAP is the HLA-B27 frequency in controls. The EF indicates the hypothetical genetic component of the disease and gives the proportion of disease cases attributable to a marker in the population (in this case, an HLA-B27 antigen), that presents a positive association (RR>1) with disease, and/or with other risk factors associated with this marker. Preventive fraction (PF) is calculated for negative association only where RR was lower than 1, according to following equation: where RR is relative risk and f is the frequency of the HLA-B27 antigen in the subgroup of patients. The PF gives the percentage of cases that can be prevented if the population is exposed to an intervention compared to unexposed population. The EF and PF values greater than 0.15 were considered to reflect positive and negative association, respectively [15,16]. The χ2 test was performed to find out if there was a significant difference of HLA-B27 antigen frequency between controls and investigated subgroups of patients, according to following formula: ( )( )( )( ) ( )2 ( ) 2 a b c d a c b d X ad bc a b c d + + + + − + + + = where a and c are the number of patients or healthy persons who have a given antigen; b and d are the number of patients or healthy persons who do not have a given antigen, respectively [17,18].



Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006